Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis
Status: | Not yet recruiting |
---|---|
Conditions: | Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any - 21 |
Updated: | 2/14/2019 |
Start Date: | February 28, 2019 |
End Date: | February 28, 2032 |
Contact: | Josh Rubin, M.D., Ph.D. |
Email: | rubin_j@wustl.edu |
Phone: | (314) 286-2790 |
The investigators will develop the concept of a sex-specific therapeutic intervention for
gliomas that is based upon dietary carbohydrate restriction. The investigators will integrate
metabolomics tools and FDG-PET imaging to validate the ketogenic diet on a sex-specific
basis.
gliomas that is based upon dietary carbohydrate restriction. The investigators will integrate
metabolomics tools and FDG-PET imaging to validate the ketogenic diet on a sex-specific
basis.
Inclusion Criteria:
- Diagnosis of a recurrent primary brain tumor with no curative therapy available.
- Measurable disease using pediatric Response Assessment in Neuro-Oncology Criteria
(RANO) criteria.
- Life expectancy > 12 weeks
- Prior treatment with radiation alone, chemotherapy alone or combined radiation and
chemotherapy is allowed.
- No more than 21 years of age.
- Normal bone marrow and organ function as defined below:
- Leukocytes ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcl
- Platelets ≥ 100,000/mcl
- Total bilirubin ≤ 1.5 x IULN
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with
creatinine levels above institutional normal
- Normal room air oxygenation must be documented. If room air oxygen saturation is
less than 97%, a diffusion capacity of carbon monoxide (DLCO) of greater than
80%, must be demonstrated.
- Karnofsky performance status of ≥ 60
- Patients of childbearing potential must agree to use adequate contraception (hormonal
or barrier method of birth control, abstinence) prior to study entry and for the
duration of study participation. Should a female patient become pregnant or suspect
she is pregnant while participating in this study, she must inform her treating
physician immediately.
- Ability to understand and willingness to sign an IRB approved written informed consent
document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Contraindicated for ketogenic diet.
- Primary and secondary carnitine deficiency
- Carnitine palmitoyltransferase I or II deficiency
- Carnitine translocase deficiency
- Mitochondrial β-oxidation defects
- Pyruvate carboxylase deficiency
- Glycogen storage diseases
- Ketolysis defects
- Ketogenesis defects
- Porphyria
- Prolonged QT syndrome
- Liver insufficiency
- Renal insufficiency
- Pancreatic insufficiency
- Pulmonary insufficiency
- Hyper insulinism
- Pregnant and/or breastfeeding. Female patients of childbearing potential must have a
negative pregnancy test within 14 days of study entry.
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Josh Rubin, M.D., Ph.D.
Phone: 314-286-2790
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials